Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

NCT02109627 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Low Accrual

Conditions

Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Ficlatuzumab
DRUG: Cytarabine

Sponsor

C. Babis Andreadis

Collaborators

[object Object]
[object Object]